Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Digestive System Diseases

Gland and Hormone Related Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Breast Neoplasms

Pancreatic Neoplasms

Colonic Neoplasms

Urinary Bladder Neoplasms

Breast Diseases

Skin Diseases

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urinary Bladder Diseases

Urologic Diseases

Male Urogenital Diseases

Colorectal Neoplasms

Intestinal Neoplasms

Colonic Diseases

Intestinal Diseases

Pancreatic Cancer

Herbal and Botanical

All Drugs and Chemicals

Cola

MLN8054 will be administered orally in multiple divided daily doses for 7 days to 21 consecutive days. A 14-day recovery period will follow each dosing period, regardless of its duration. MLN8054 will be supplied in capsules of 5 mg or 25 mg with dose strength expressed as the milligrams of active drug (free acid). MLN8054 will be given on an empty stomach. Patients will be instructed to take nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose.

MLN8054

The purpose of this study is to determine (1) The side effects or toxicities of MLN8054;(2) The highest dose where side effects or toxicities are not too severe; (3) How MLN8054 is absorbed into the general blood circulation and eliminated from the body; and (4) The levels of MLN8054 in the blood that are needed to inhibit Aurora A kinase.

A Study of MLN8054 in Patients With Advanced Solid Tumors

An Open-Label, Dose Escalation Phase 1 Study of MLN8054, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors

Millennium Pharmaceuticals, Inc.

Clinical Study Medical Monitor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of MLN8054 in Patients With Advanced Solid Tumors	NCT00249301	Breast Neoplasm Colon Neoplasm Pancreatic Neop... Bladder Neoplas...	MLN8054	18 Years -	Millennium Pharmaceuticals, Inc.
A Study of MLN8054 in Patients With Advanced Solid Tumors	NCT00249301	Breast Neoplasm Colon Neoplasm Pancreatic Neop... Bladder Neoplas...	MLN8054	18 Years -	Millennium Pharmaceuticals, Inc.

Spots Global Cancer Trial Database for mln8054

Every month we try and update this database with for mln8054 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for mln8054

Every month we try and update this database with for mln8054 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for mln8054 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.